lifitegrast sold brand name xiidra medication treatment signs symptoms dry eye syndrome called keratoconjunctivitis sicca lifitegrast reduces inflammation inhibiting inflammatory cell often used conjunction ciclosporin ikervis restasis cequa dry eye treatment including meibomian gland dysfunction inflammatory dry eye common side effects clinical trials eye irritation discomfort blurred vision dysgeusia distortion sense lifitegrast supplied eye drop lifitegrast inhibits integrin lymphocyte functionassociated antigen binding intercellular adhesion molecule mechanism downregulates inflammation mediated lifitegrast initially designed sunesis developed sarcode acquired shire submitted new drug application us food drug administration fda march fda granted shire priority review month later requested additional clinical data supplied january approval granted july lifitegrast approved health canada january available canadian pharmacies march shire acquired takeda pharmaceutical company late may novartis reached agreement purchase assets associated lifitegrast novartis pay takeda upfront payment billion latter drugmaker eligible milestone payments much billion novartis noted drug amassed approximately million revenue novartis sold assets bausch lomb billion eligible additional million payments linked future sales xiidra well two pipeline httpsenwikipediaorgwikilifitegrast